Our findings showed that in AR− prostate cancer cells, DU-145, ALA treatment significantly reduced ROS production, simultaneously downregulating the protein expression of two key antioxidant enzymes, SOD1 and GSTP1, thus suggesting that ALA may affect the oxidative/redox imbalance of prostate cancer cells that favor and sustain cancer cells survival. Here, SOD1 is linked to prostate carcinoma.